Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 safety and immunogenicity study of quadrivalent influenza vaccine versus trivalent influenza vaccine
2011-005101-79Phase 3
- Sponsor
- Sanofi
- Start
- Oct 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of influenza vaccine in influenza (2 arms), sponsored by Sanofi. Primary endpoints: Safety profile and Lot-to-lot immunogenicity equivalence.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2011-005101-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005101-79.